{"success":true,"data":{"pressRelease":{"id":"25670","rtpr_id":"nGNXc0D1Vs","ticker":"CVKD","exchange":"NASDAQ","all_tickers":["CVKD"],"title":"Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA","author":"Globe Newswire","published_at":"2026-05-07T12:30:01.275Z","article_body":"PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics,\nInc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel\ntherapies for life-threatening immune and thrombotic conditions, today\nreported its financial results for the first quarter ended March 31, 2026, and\nprovided a corporate update highlighting continued progress in its CAD-1005\nprogram for HIT. The Company has now received the official minutes from its\nEnd-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration\n(FDA), which provided guidance on key elements of the planned pivotal Phase 3\nregistration trial for CAD-1005, Cadrenal's investigational first-in-class\n12-lipoxygenase (12-LOX) inhibitor being developed to treat suspected\nheparin-induced thrombocytopenia (HIT). Based on this feedback and Phase 2\ndata, Cadrenal plans to advance directly to a randomized, blinded,\nplacebo-controlled Phase 3 study evaluating CAD-1005 added to standard-of-care\nanticoagulation in patients with HIT.\n\nRecent Highlights\n* Received official FDA EOP2 meeting minutes providing guidance on protocol\ndesign, study population, dosing, background therapy, exposure, safety\ndatabase, and the primary endpoint of new or worsening thrombotic events.\n* After considering FDA feedback on a pivotal registration study, Cadrenal\nplans to advance directly to a randomized, blinded, placebo-controlled Phase 3\nstudy evaluating CAD-1005 added to the current standard of care for patients\nwith HIT.\n* Planned pivotal Phase 3 study, the first randomized, blinded,\nplacebo-controlled registration trial in HIT, will evaluate CAD-1005 in\napproximately 120 patients across clinical centers worldwide and is intended\nto support a projected NDA submission in 2029.\n* Primary endpoint, centrally adjudicated, is expected to be the incidence of\nnew or worsening thrombotic events in patients with Serotonin Release Assay\n(SRA)-confirmed HIT, with at least one planned interim analysis.\n* Phase 2 data showed an absolute reduction of more than 25% in thrombotic\nevents when CAD-1005 was added to standard anticoagulant therapy, supporting\nthe continued advancement of CAD-1005 as Cadrenal's near-term development\npriority.\n* Continues to position CAD-1005 as a first-in-class, selective 12-LOX\ninhibitor and the only treatment in clinical development that targets the\nunderlying immune drivers of HIT, supported by Orphan Drug and Fast Track\ndesignations from the FDA and by orphan drug status from the European\nMedicines Agency.\n\"With the official EOP2 meeting minutes now in hand, we believe the\nregistration path for CAD-1005 in HIT is clearly defined,\" commented Quang X.\nPham, Chairman & CEO. \"The FDA's guidance on trial design and the primary\nendpoint of new or worsening thrombotic events reinforces our confidence in\nadvancing directly to a pivotal Phase 3 study. We believe CAD-1005 has the\npotential to be the first new therapy for HIT in more than two decades.\"\n\nFirst Quarter 2026 Financial Highlights\n\nResearch and development expenses for the quarter ended March 31, 2026, were\n$0.8 million compared to $1.7 million for the same period in 2025. General and\nadministrative expenses were $1.7 million compared to $2.3 million for the\nsame period in 2025. Total operating expenses were $2.5 million compared to\n$3.9 million for the same period in 2025. Cadrenal reported a net loss of $2.5\nmillion for the quarter ended March 31, 2026, compared to $3.8 million for the\nsame period in 2025.\n\nAs of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million.\nSubsequent to quarter end, on April 1, 2026, the Company completed a $2.5\nmillion financing, providing additional capital to support near-term\ndevelopment activities. The Company continues to evaluate financing and\nstrategic alternatives to support its planned clinical development activities,\nincluding the anticipated pivotal Phase 3 trial of CAD-1005 in HIT.\n\nThe Company is advancing Phase 3 readiness activities, including protocol\nfinalization, and expects to provide further updates in the coming quarters.\n\nAbout Cadrenal Therapeutics, Inc.\n\nCadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company\nadvancing novel therapies for life-threatening immune and thrombotic\nconditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor\nbeing developed to treat heparin-induced thrombocytopenia (HIT), a deadly\nimmune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and\nFast Track designations from the U.S. Food and Drug Administration and orphan\ndrug status from the European Medicines Agency. Second-generation 12-LOX oral\ntherapeutics are also in development for chronic indications.\n\nThe Company’s broader pipeline includes tecarfarin, a late-stage oral\nvitamin K antagonist designed to prevent heart attacks, strokes, and deaths\nfrom blood clots in patients requiring chronic anticoagulation, including\nthose with end-stage kidney disease and those with left ventricular assist\ndevices, and frunexian, a parenteral Factor XIa inhibitor intended for use in\nacute hospital settings.\n\nFor more information, visit https://www.cadrenal.com/ and connect with the\nCompany on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pHUvoc8oB6iymqldOYBvyO2EVwbqtxaFRouMgXjuD_Tugw-xWr58ihlbqcd7yE9pYVvAO9UPsdUuZwU6LZbAxI_-BPcVLs3LoNOyqBKauBFjkuWtc7HwfRos41DUpLS_JgO0SQ5yavbG2YYc3aITTQ==).\n\nSafe Harbor\n\nAny statements in this press release about future expectations, plans, and\nprospects, as well as any other statements regarding matters that are not\nhistorical facts, may constitute \"forward-looking statements.\" The words\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"plan,\" \"potentially,\" \"predict,\" \"project,\" \"should,\" \"target,\"\n\"will,\" \"would\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. These statements include, without limitation,\nstatements regarding continued progress in its CAD-1005 program for HIT ;\nplans to advance directly to a randomized, blinded, placebo-controlled Phase 3\nstudy evaluating CAD-1005 added to standard-of-care anticoagulation in\npatients with HIT; the planned pivotal Phase 3 study being the first\nrandomized, blinded, placebo-controlled registration trial in HIT; the Phase 3\nstudy evaluating CAD-1005 in approximately 120 patients across clinical\ncenters worldwide; the trial supporting a projected NDA submission in 2029;\nthe incidence of new or worsening thrombotic events in patients with Serotonin\nRelease Assay (SRA)-confirmed HIT being the primary endpoint of the trial; the\ntrial having at least one planned interim analysis; continuing to position\nCAD-1005 as a first-in-class, selective 12-LOX inhibitor and the only\ntreatment in clinical development that targets the underlying immune drivers\nof HIT; the registration path for CAD-1005 in HIT being clearly defined; and\nCAD-1005 having the potential to be the first new therapy for HIT in more than\ntwo decades. Actual results may differ materially from those indicated by such\nforward-looking statements as a result of various important factors, including\nthe ability to raise sufficient capital to continue progress of CAD-1005; the\nability to advance directly to a randomized, blinded, placebo-controlled Phase\n3 study evaluating CAD-1005 added to standard-of-care anticoagulation in\npatients with HIT; the ability to successfully design and complete the Phase 3\nstudy and derive the results needed for an NDA submission: and the other risk\nfactors described in the Company's Annual Report on Form 10-K for the year\nended December 31, 2025, and the Company's subsequent filings with the\nSecurities and Exchange Commission, including subsequent periodic reports on\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any\nforward-looking statements contained in this press release speak only as of\nthe date hereof and, except as required by federal securities laws, the\nCompany specifically disclaims any obligation to update any forward-looking\nstatement, whether as a result of new information, future events, or\notherwise.\n\nFor more information, please contact:\n\nLytham Partners, LLC\nRobert Blum, Managing Partner\n602-889-9700\nCVKD@lythampartners.com\n\n \n CADRENAL THERAPEUTICS, INC. \n BALANCE SHEETS \n \n March 31, 2026 December 31, \n (unaudited) 2025 \n Assets: \n Current assets: \n Cash and cash equivalents $ 2,308,137 $ 4,007,789 \n Interest receivable 5,466 5,096 \n Prepaid expenses and other current assets 428,071 200,140 \n Deferred offering costs 113,607 106,342 \n Total current assets 2,855,281 4,319,367 \n Property, plant and equipment, net 4,619 5,174 \n Other assets 2,167 2,167 \n Total assets $ 2,862,067 $ 4,326,708 \n Liabilities and Stockholders' Equity: \n Current liabilities: \n Accounts payable $ 824,809 $ 650,663 \n Accrued liabilities 240,143 937,319 \n Total current liabilities 1,064,952 1,587,982 \n Total liabilities 1,064,952 1,587,982 \n Stockholders’ equity: \n Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 - - \n Common stock, $0.001 par value; 75,000,000 shares authorized, 2,506,817 shares issued and outstanding as of March 31, 2026; 2,338,127 shares issued and outstanding as of December 31, 2025 2,507 2,338 \n Additional paid-in capital 43,251,293 41,696,533 \n Accumulated deficit (41,456,685 ) (38,960,145 ) \n Total stockholders’ equity 1,797,115 2,738,726 \n Total liabilities and stockholders’ equity $ 2,862,067 $ 4,326,708 \n \n\n\n\n CADRENAL THERAPEUTICS, INC. \n STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS \n (unaudited) \n Three Months Ended \n March 31, \n 2026 2025 \n Operating expenses: \n General and administrative expenses $ 1,742,315 $ 2,254,577 \n Research and development expenses 771,508 1,667,882 \n Depreciation expense 555 5,517 \n Total operating expenses 2,514,378 3,927,976 \n Loss from operations (2,514,378 ) (3,927,976 ) \n Other income \n Interest and dividend income 17,838 82,596 \n Total other income 17,838 82,596 \n Net loss and comprehensive loss $ (2,496,540 ) $ (3,845,380 ) \n \n Net loss per common share, basic and diluted $ (1.04 ) $ (2.09 ) \n Weighted average number of common shares used in computing net loss per common share, basic and diluted 2,407,665 1,844,072 \n \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dec0fe5d-b262-4ca7-94e0-1fd3856d07a8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc0D1Vs","title":"Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA","author":"Globe Newswire","ticker":"CVKD","created":"2026-05-07T12:30:01.275Z","tickers":["CVKD"],"exchange":"NASDAQ","article_body":"PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics,\nInc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel\ntherapies for life-threatening immune and thrombotic conditions, today\nreported its financial results for the first quarter ended March 31, 2026, and\nprovided a corporate update highlighting continued progress in its CAD-1005\nprogram for HIT. The Company has now received the official minutes from its\nEnd-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration\n(FDA), which provided guidance on key elements of the planned pivotal Phase 3\nregistration trial for CAD-1005, Cadrenal's investigational first-in-class\n12-lipoxygenase (12-LOX) inhibitor being developed to treat suspected\nheparin-induced thrombocytopenia (HIT). Based on this feedback and Phase 2\ndata, Cadrenal plans to advance directly to a randomized, blinded,\nplacebo-controlled Phase 3 study evaluating CAD-1005 added to standard-of-care\nanticoagulation in patients with HIT.\n\nRecent Highlights\n* Received official FDA EOP2 meeting minutes providing guidance on protocol\ndesign, study population, dosing, background therapy, exposure, safety\ndatabase, and the primary endpoint of new or worsening thrombotic events.\n* After considering FDA feedback on a pivotal registration study, Cadrenal\nplans to advance directly to a randomized, blinded, placebo-controlled Phase 3\nstudy evaluating CAD-1005 added to the current standard of care for patients\nwith HIT.\n* Planned pivotal Phase 3 study, the first randomized, blinded,\nplacebo-controlled registration trial in HIT, will evaluate CAD-1005 in\napproximately 120 patients across clinical centers worldwide and is intended\nto support a projected NDA submission in 2029.\n* Primary endpoint, centrally adjudicated, is expected to be the incidence of\nnew or worsening thrombotic events in patients with Serotonin Release Assay\n(SRA)-confirmed HIT, with at least one planned interim analysis.\n* Phase 2 data showed an absolute reduction of more than 25% in thrombotic\nevents when CAD-1005 was added to standard anticoagulant therapy, supporting\nthe continued advancement of CAD-1005 as Cadrenal's near-term development\npriority.\n* Continues to position CAD-1005 as a first-in-class, selective 12-LOX\ninhibitor and the only treatment in clinical development that targets the\nunderlying immune drivers of HIT, supported by Orphan Drug and Fast Track\ndesignations from the FDA and by orphan drug status from the European\nMedicines Agency.\n\"With the official EOP2 meeting minutes now in hand, we believe the\nregistration path for CAD-1005 in HIT is clearly defined,\" commented Quang X.\nPham, Chairman & CEO. \"The FDA's guidance on trial design and the primary\nendpoint of new or worsening thrombotic events reinforces our confidence in\nadvancing directly to a pivotal Phase 3 study. We believe CAD-1005 has the\npotential to be the first new therapy for HIT in more than two decades.\"\n\nFirst Quarter 2026 Financial Highlights\n\nResearch and development expenses for the quarter ended March 31, 2026, were\n$0.8 million compared to $1.7 million for the same period in 2025. General and\nadministrative expenses were $1.7 million compared to $2.3 million for the\nsame period in 2025. Total operating expenses were $2.5 million compared to\n$3.9 million for the same period in 2025. Cadrenal reported a net loss of $2.5\nmillion for the quarter ended March 31, 2026, compared to $3.8 million for the\nsame period in 2025.\n\nAs of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million.\nSubsequent to quarter end, on April 1, 2026, the Company completed a $2.5\nmillion financing, providing additional capital to support near-term\ndevelopment activities. The Company continues to evaluate financing and\nstrategic alternatives to support its planned clinical development activities,\nincluding the anticipated pivotal Phase 3 trial of CAD-1005 in HIT.\n\nThe Company is advancing Phase 3 readiness activities, including protocol\nfinalization, and expects to provide further updates in the coming quarters.\n\nAbout Cadrenal Therapeutics, Inc.\n\nCadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company\nadvancing novel therapies for life-threatening immune and thrombotic\nconditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor\nbeing developed to treat heparin-induced thrombocytopenia (HIT), a deadly\nimmune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and\nFast Track designations from the U.S. Food and Drug Administration and orphan\ndrug status from the European Medicines Agency. Second-generation 12-LOX oral\ntherapeutics are also in development for chronic indications.\n\nThe Company’s broader pipeline includes tecarfarin, a late-stage oral\nvitamin K antagonist designed to prevent heart attacks, strokes, and deaths\nfrom blood clots in patients requiring chronic anticoagulation, including\nthose with end-stage kidney disease and those with left ventricular assist\ndevices, and frunexian, a parenteral Factor XIa inhibitor intended for use in\nacute hospital settings.\n\nFor more information, visit https://www.cadrenal.com/ and connect with the\nCompany on LinkedIn\n(https://www.globenewswire.com/Tracker?data=pHUvoc8oB6iymqldOYBvyO2EVwbqtxaFRouMgXjuD_Tugw-xWr58ihlbqcd7yE9pYVvAO9UPsdUuZwU6LZbAxI_-BPcVLs3LoNOyqBKauBFjkuWtc7HwfRos41DUpLS_JgO0SQ5yavbG2YYc3aITTQ==).\n\nSafe Harbor\n\nAny statements in this press release about future expectations, plans, and\nprospects, as well as any other statements regarding matters that are not\nhistorical facts, may constitute \"forward-looking statements.\" The words\n\"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"plan,\" \"potentially,\" \"predict,\" \"project,\" \"should,\" \"target,\"\n\"will,\" \"would\" and similar expressions are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these identifying words. These statements include, without limitation,\nstatements regarding continued progress in its CAD-1005 program for HIT ;\nplans to advance directly to a randomized, blinded, placebo-controlled Phase 3\nstudy evaluating CAD-1005 added to standard-of-care anticoagulation in\npatients with HIT; the planned pivotal Phase 3 study being the first\nrandomized, blinded, placebo-controlled registration trial in HIT; the Phase 3\nstudy evaluating CAD-1005 in approximately 120 patients across clinical\ncenters worldwide; the trial supporting a projected NDA submission in 2029;\nthe incidence of new or worsening thrombotic events in patients with Serotonin\nRelease Assay (SRA)-confirmed HIT being the primary endpoint of the trial; the\ntrial having at least one planned interim analysis; continuing to position\nCAD-1005 as a first-in-class, selective 12-LOX inhibitor and the only\ntreatment in clinical development that targets the underlying immune drivers\nof HIT; the registration path for CAD-1005 in HIT being clearly defined; and\nCAD-1005 having the potential to be the first new therapy for HIT in more than\ntwo decades. Actual results may differ materially from those indicated by such\nforward-looking statements as a result of various important factors, including\nthe ability to raise sufficient capital to continue progress of CAD-1005; the\nability to advance directly to a randomized, blinded, placebo-controlled Phase\n3 study evaluating CAD-1005 added to standard-of-care anticoagulation in\npatients with HIT; the ability to successfully design and complete the Phase 3\nstudy and derive the results needed for an NDA submission: and the other risk\nfactors described in the Company's Annual Report on Form 10-K for the year\nended December 31, 2025, and the Company's subsequent filings with the\nSecurities and Exchange Commission, including subsequent periodic reports on\nQuarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any\nforward-looking statements contained in this press release speak only as of\nthe date hereof and, except as required by federal securities laws, the\nCompany specifically disclaims any obligation to update any forward-looking\nstatement, whether as a result of new information, future events, or\notherwise.\n\nFor more information, please contact:\n\nLytham Partners, LLC\nRobert Blum, Managing Partner\n602-889-9700\nCVKD@lythampartners.com\n\n \n CADRENAL THERAPEUTICS, INC. \n BALANCE SHEETS \n \n March 31, 2026 December 31, \n (unaudited) 2025 \n Assets: \n Current assets: \n Cash and cash equivalents $ 2,308,137 $ 4,007,789 \n Interest receivable 5,466 5,096 \n Prepaid expenses and other current assets 428,071 200,140 \n Deferred offering costs 113,607 106,342 \n Total current assets 2,855,281 4,319,367 \n Property, plant and equipment, net 4,619 5,174 \n Other assets 2,167 2,167 \n Total assets $ 2,862,067 $ 4,326,708 \n Liabilities and Stockholders' Equity: \n Current liabilities: \n Accounts payable $ 824,809 $ 650,663 \n Accrued liabilities 240,143 937,319 \n Total current liabilities 1,064,952 1,587,982 \n Total liabilities 1,064,952 1,587,982 \n Stockholders’ equity: \n Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 - - \n Common stock, $0.001 par value; 75,000,000 shares authorized, 2,506,817 shares issued and outstanding as of March 31, 2026; 2,338,127 shares issued and outstanding as of December 31, 2025 2,507 2,338 \n Additional paid-in capital 43,251,293 41,696,533 \n Accumulated deficit (41,456,685 ) (38,960,145 ) \n Total stockholders’ equity 1,797,115 2,738,726 \n Total liabilities and stockholders’ equity $ 2,862,067 $ 4,326,708 \n \n\n\n\n CADRENAL THERAPEUTICS, INC. \n STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS \n (unaudited) \n Three Months Ended \n March 31, \n 2026 2025 \n Operating expenses: \n General and administrative expenses $ 1,742,315 $ 2,254,577 \n Research and development expenses 771,508 1,667,882 \n Depreciation expense 555 5,517 \n Total operating expenses 2,514,378 3,927,976 \n Loss from operations (2,514,378 ) (3,927,976 ) \n Other income \n Interest and dividend income 17,838 82,596 \n Total other income 17,838 82,596 \n Net loss and comprehensive loss $ (2,496,540 ) $ (3,845,380 ) \n \n Net loss per common share, basic and diluted $ (1.04 ) $ (2.09 ) \n Weighted average number of common shares used in computing net loss per common share, basic and diluted 2,407,665 1,844,072 \n \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dec0fe5d-b262-4ca7-94e0-1fd3856d07a8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-07T12:30:01.344841997Z","server_sent_at_ms":1778157001344},"received_at":"2026-05-07T12:30:01.471Z","source_url":null},"analysis":{"id":"20095","press_release_id":"25670","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Low cash runway: Q1 burn of $2.5M against cash position of $2.3M and recent financing of $2.5M implies limited liquidity without further capital raises."],"eventType":"earnings","narrative":"Cadrenal Therapeutics received official minutes from its FDA End-of-Phase 2 meeting, establishing the path to advance CAD-1005 directly into a pivotal Phase 3 registration trial for HIT.\n\nThe randomized, placebo-controlled study is planned for approximately 120 patients worldwide, with a primary endpoint of new or worsening thrombotic events and a target NDA submission in 2029.\n\nQ1 financial results showed a net loss of $2.5 million, or $(1.04) per share, with cash position of $2.3 million bolstered by a $2.5 million financing closed in early April.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"FDA agreement clears path for pivotal Phase 3 trial of lead asset CAD-1005."},"keyFigures":{"customDimensions":{"cash":2308137,"ga_expenses":1742315,"rd_expenses":771508,"phase_3_patients":120,"financing_proceeds":2500000,"operating_expenses":2514378,"projected_nda_submission":"2029"}},"quotedText":"With the official EOP2 meeting minutes now in hand, we believe the registration path for CAD-1005 in HIT is clearly defined","namedEntities":{"people":[{"name":"Quang X. Pham","role":"Chairman & CEO"}],"products":["CAD-1005","tecarfarin","frunexian"],"companies":[{"name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"European Medicines Agency","relationship":"regulator"},{"name":"Lytham Partners, LLC","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$0.8 million","context":"Q1 2026 research and development expenses"},{"amount":"$1.7 million","context":"Q1 2026 general and administrative expenses"},{"amount":"$2.5 million","context":"Q1 2026 net loss"},{"amount":"$2.3 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"$2.5 million","context":"Financing completed April 1, 2026"}]},"materialImpact":{"score":4,"reasoning":"Receipt of FDA End-of-Phase 2 minutes and agreement to proceed directly to a pivotal Phase 3 trial represents a major de-risking event for the company's lead asset. This clears the regulatory path for CAD-1005, though the small cash position requires continued funding vigilance."},"tickerRelevance":{"others":[],"primary":"CVKD"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"phase-3-go-ahead","sectorWeight":"biotech","cashPositionRisk":"high"}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Cadrenal Therapeutics received official minutes from its FDA End-of-Phase 2 meeting, establishing the path to advance CAD-1005 directly into a pivotal Phase 3 registration trial for HIT.\n\nThe randomized, placebo-controlled study is planned for approximately 120 patients worldwide, with a primary endpoint of new or worsening thrombotic events and a target NDA submission in 2029.\n\nQ1 financial results showed a net loss of $2.5 million, or $(1.04) per share, with cash position of $2.3 million bolstered by a $2.5 million financing closed in early April.","key_figures":{"customDimensions":{"cash":2308137,"ga_expenses":1742315,"rd_expenses":771508,"phase_3_patients":120,"financing_proceeds":2500000,"operating_expenses":2514378,"projected_nda_submission":"2029"}},"named_entities":{"people":[{"name":"Quang X. Pham","role":"Chairman & CEO"}],"products":["CAD-1005","tecarfarin","frunexian"],"companies":[{"name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"},{"name":"European Medicines Agency","relationship":"regulator"},{"name":"Lytham Partners, LLC","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$0.8 million","context":"Q1 2026 research and development expenses"},{"amount":"$1.7 million","context":"Q1 2026 general and administrative expenses"},{"amount":"$2.5 million","context":"Q1 2026 net loss"},{"amount":"$2.3 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"$2.5 million","context":"Financing completed April 1, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-07T22:26:03.908Z","global_importance":30,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"phase-3-go-ahead","sectorWeight":"biotech","cashPositionRisk":"high"}},"durationMs":null,"modelName":"glm-4.7"}}